Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.37 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.37 |
| ▸ | P2RY12 | Q9H244 | 9/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.35 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.35 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.34 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.34 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21726072 | 0.98 | KDM4E (0.41) | KDM4ETAS1R3TAS1R1P2RY12ADORA1 | |
| SCHEMBL22336847 | 0.94 | KDM4E (0.41) | KDM4ETAS1R3TAS1R1P2RY12ADORA1 | |
| SCHEMBL20341120 | 0.93 | KDM4E (0.39) | KDM4ETAS1R3TAS1R1P2RY12ADORA1 | |
| SCHEMBL21726064 | 0.92 | KDM4E (0.42) | KDM4ETAS1R3TAS1R1P2RY12ADORA1 | |
| SCHEMBL22337034 | 0.92 | KDM4E (0.46) | KDM4ETAS1R3TAS1R1 | |
| SCHEMBL21726065 | 0.92 | KDM4E (0.40) | KDM4ETAS1R3TAS1R1P2RY12ADORA1 | |
| SCHEMBL21726081 | 0.90 | KDM4E (0.47) | KDM4ETAS1R3TAS1R1 | |
| SCHEMBL22336699 | 0.89 | KDM4E (0.40) | KDM4ETAS1R3TAS1R1P2RY12P2RY2 | |
| SCHEMBL20341099 | 0.88 | KDM4E (0.38) | KDM4ETAS1R3TAS1R1P2RY12ADORA1 | |
| SCHEMBL20341141 | 0.88 | KDM4E (0.49) | KDM4ETAS1R3TAS1R1ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11053272-B2 | Cyclic dinucleotides for cytokine induction | KAYLA THERAPEUTICS (FR) | 2021-07-06 | — | — | US | disclosed |
| US-20200255469-A1 | CYCLIC DINUCLEOTIDES FOR CYTOKINE INDUCTION | KAYLA THERAPEUTICS (FR) | 2020-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11053272-B2 | Cyclic dinucleotides for cytokine induction | IL1B, IFNG, IFNAR1 | KDM4E 3469/4885TAS1R3 4300/4885TAS1R1 2754/4885 |
| US-20200255469-A1 | CYCLIC DINUCLEOTIDES FOR CYTOKINE INDUCTION | IL1B, IFNG, IFNAR1 | KDM4E 3469/4885TAS1R3 4300/4885TAS1R1 2754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.